John Libbey Eurotext

Hématologie

La polymédication a-t-elle un effet nocif chez les patients âgés atteints de leucémie myéloïde chronique traités par imatinib ? Volume 22, numéro 6, Novembre-Décembre 2016

  • [1] Sauselle S., el al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study. Blood. 2015;126:42-49.
  • [2] Efficace F., Rosti G., Breccia M. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Ann Hematol. 2016;95:211-219.
  • [3] Iurlo A., Nobili A., Latagliata R. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget. 2016. Aug 27. doi: 10.18632/oncotarget.11657 [Epub ahead of print]